Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2012 Sep;5(3):622-6.
doi: 10.1159/000345369. Epub 2012 Sep 20.

Neoadjuvant Chemotherapy With Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor

Affiliations
Free PMC article
Case Reports

Neoadjuvant Chemotherapy With Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor

Sumana Devata et al. Case Rep Oncol. .
Free PMC article

Abstract

Pancreatic neuroendocrine tumors (PNETs) are relatively rare tumors that arise in the endocrine cells of the pancreas. Historically, somatostatin analogues have been used in this disease primarily for symptom control and, to a limited extent, disease stability. More recently, sunitinib and everolimus have been approved for advanced stage PNETs based on a survival benefit. However, both agents have a <10% actual response rate and cause nontrivial side effect profiles that limit duration of therapy. In locally advanced disease, there is a paucity of data to support an optimal neoadjuvant approach with the expectation of down-staging to allow for curative resection. We describe in this case a young woman who was successfully down-staged using a chemotherapy regimen of capecitabine and temozolomide with minimal toxicity.

Keywords: Capecitabine; Pancreatic neuroendocrine tumor; Temozolomide.

Figures

Fig. 1
Fig. 1
CT findings of pancreatic mass. a, b Prior to neoadjuvant chemotherapy. c, d After 8 cycles of neoadjuvant everolimus and temozolomide.

Similar articles

See all similar articles

Cited by 5 articles

References

    1. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Annals of Oncology. 2008;19:1727–1733. - PMC - PubMed
    1. Yao JC, Hassan M, et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072. - PubMed
    1. Oberg K, Knigge U, et al. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl. 7):vii124–viii130. - PubMed
    1. Rinke A, Müller HH. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–4663. - PubMed
    1. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–523. - PMC - PubMed

Publication types

Feedback